The Utility of Hyperthermic Intraperitoneal Chemotherapy

Valerie Francescutti, MD, FRCSC, assistant professor, Surgical Oncology, Roswell Park Cancer Institute (RPCI), discusses the utility of hyperthermic intraperitoneal chemotherapy (HIPEC).

Clinical Pearls

Valerie Francescutti, MD, FRCSC, assistant professor, Surgical Oncology, Roswell Park Cancer Institute (RPCI), discusses the utility of hyperthermic intraperitoneal chemotherapy (HIPEC).

  • HIPEC involves removing all cancer from a patient’s abdominal cavity and providing heated chemotherapy for the management of any microscopic tumors
  • Indications for HIPEC include colorectal cancer that has resulted in peritoneal metastases, appendiceal cancer, and peritoneal mesothelioma
  • At RPCI, 50-60% of patients treated with HIPEC have appendiceal or colorectal cancers